SynthesisCNS drugs2026
Memantine Augmentation in Obsessive-Compulsive Disorder: A Systematic Review and Meta-analysis.
Synthesis in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObsessive-compulsive disorder (OCD) remains challenging to treat despite established treatments.
objectiveSince glutamatergic dysregulation is implicated in OCD, we systematically reviewed and meta-analysed randomized controlled trials (RCTs) comparing adjunctive memantine versus placebo for OCD.
methodsWe searched CENTRAL, Embase, MEDLINE, PsycINFO, PubMed, Web of Science, Scopus, and trial registries from inception to September 2025 for RCTs of adjunctive memantine in adults with OCD [PROSPERO: CRD420251147106]. The primary outcome was endpoint Yale-Brown Obsessive Compulsive Scale score. Random-effects models used REML estimation with Hartung-Knapp-Sidik-Jonkman confidence intervals. Risk of bias was assessed with RoB 2 and certainty of evidence with GRADE.
resultsSix RCTs (n = 288; 8-16 weeks; 5-20 mg/day) met inclusion criteria. Overall, memantine did not produce a statistically significant symptom reduction versus placebo (pooled mean difference -3.74 points, 95% confidence interval [CI] -9.95 to 2.47), with high heterogeneity (I
conclusionsMemantine is not supported for routine use in unselected OCD. In treatment-resistant OCD, current evidence supports a hypothesis-generating signal that may justify cautious off-label discussion when established augmenters are unsuitable. An adequately powered RCT in refractory OCD is warranted.
Indexed as
Identifiers
42484816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.